{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:36:57Z","timestamp":1794940617395,"version":"4.9.1"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>The Safety, Tolerability, and Efficacy of Rapid Optimization, Helped by N-Terminal Pro\u2013Brain Natriuretic Peptide Testing of Heart Failure Therapies (STRONG-HF) trial strived for rapid uptitration aiming to reach 100% optimal doses of guideline-directed medical therapy (GDMT) within 2 weeks after discharge from an acute heart failure (AHF) admission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the association between degree of GDMT doses achieved in high-intensity care and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This was a post hoc secondary analysis of the STRONG-HF randomized clinical trial, conducted from May 2018 to September 2022. Included in the study were patients with AHF who were not treated with optimal doses of GDMT before and after discharge from an AHF admission. Data were analyzed from January to October 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>The mean percentage of the doses of 3 classes of HF medications (renin-angiotensin system inhibitors, \u03b2-blockers, and mineralocorticoid receptor antagonists) relative to their optimal doses was computed. Patients were classified into 3 dose categories: low (&amp;amp;lt;50%), medium (\u226550% to &amp;amp;lt;90%), and high (\u226590%). Dose and dose group were included as a time-dependent covariate in Cox regression models, which were used to test whether outcomes differed by dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measures<\/jats:title>\n                    <jats:p>Post hoc secondary analyses of postdischarge 180-day HF readmission or death and 90-day change in quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 515 patients (mean [SD] age, 62.7 [13.4] years; 311 male [60.4%]) assigned high-intensity care were included in this analysis. At 2 weeks, 39 patients (7.6%) achieved low doses, 254 patients (49.3%) achieved medium doses, and 222 patients (43.1%) achieved high doses. Patients with lower blood pressure and more congestion were less likely to be uptitrated to optimal GDMT doses at week 2. As a continuous time-dependent covariate, an increase of 10% in the average percentage optimal dose was associated with a reduction in 180-day HF readmission or all-cause death (primary end point: adjusted hazard ratio [aHR], 0.89; 95% CI, 0.81-0.98;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.01) and a decrease in 180-day all-cause mortality (aHR, 0.84; 95% CI, 0.73-0.95;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.007). Quality of life at 90 days, measured by the EQ-5D visual analog scale, improved more in patients treated with higher doses of GDMT (mean difference, 0.10; 95% CI, \u22124.88 to 5.07 and 3.13; 95% CI, \u22121.98 to 8.24 points in the medium- and high-dose groups relative to the low-dose group, respectively;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.07). Adverse events to day 90 occurred less frequently in participants with HIC who were prescribed higher GDMT doses at week 2.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Results of this post hoc analysis of the STRONG-HF randomized clinical trial show that, among patients randomly assigned to high-intensity care, achieving higher doses of HF GDMT 2 weeks after discharge was feasible and safe in most patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03412201\">NCT03412201<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamacardio.2023.4553","type":"journal-article","created":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T11:33:04Z","timestamp":1703676784000},"page":"114","source":"Crossref","is-referenced-by-count":81,"title":["Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission"],"prefix":"10.1001","volume":"9","author":[{"given":"Gad","family":"Cotter","sequence":"first","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM UMR-S 942(MASCOT), Paris, France"},{"name":"Momentum Research Inc, Durham, North Carolina"},{"name":"Heart Initiative, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Deniau","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM UMR-S 942(MASCOT), Paris, France"},{"name":"Department of Anesthesiology and Critical Care and Burn Unit, Saint-Louis and Lariboisi\u00e8re Hospitals, FHU PROMICE, DMU Parabol, APHP.Nord, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Davison","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM UMR-S 942(MASCOT), Paris, France"},{"name":"Momentum Research Inc, Durham, North Carolina"},{"name":"Heart Initiative, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Edwards","sequence":"additional","affiliation":[{"name":"Momentum Research Inc, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Adamo","sequence":"additional","affiliation":[{"name":"Cardiology, ASST Spedali Civili and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Arrigo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Stadtspital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianela","family":"Barros","sequence":"additional","affiliation":[{"name":"Momentum Research Inc, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Biegus","sequence":"additional","affiliation":[{"name":"Institute of Heart Diseases, Wroclaw Medical University, Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Celutkiene","sequence":"additional","affiliation":[{"name":"Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil\u0117","family":"\u010cerlinskait\u0117-Bajor\u0117","sequence":"additional","affiliation":[{"name":"Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidiu","family":"Chioncel","sequence":"additional","affiliation":[{"name":"Emergency Institute for Cardiovascular Diseases \u201cProf. C.C.Iliescu,\u201d University of Medicine \u201cCarol Davila,\u201d Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Cohen-Solal","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM UMR-S 942(MASCOT), Paris, France"},{"name":"Department of Cardiology, APHP Nord, Lariboisi\u00e8re University Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albertino","family":"Damasceno","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Diaz","sequence":"additional","affiliation":[{"name":"Estudios Cl\u00ednicos Latinoam\u00e9rica, Instituto Cardiovascular de Rosario, Rosario, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Gayat","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM UMR-S 942(MASCOT), Paris, France"},{"name":"Department of Anesthesiology and Critical Care and Burn Unit, Saint-Louis and Lariboisi\u00e8re Hospitals, FHU PROMICE, DMU Parabol, APHP.Nord, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Kimmoun","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Nancy; INSERM, D\u00e9faillance Circulatoire Aigue et Chronique; Service de M\u00e9decine Intensive et R\u00e9animation Brabois, CHRU de Nancy, 54511 Vandoeuvre-l\u00e8s-Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore and Duke-National University of Singapore, Singapore"},{"name":"Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Cardiology, ASST Spedali Civili and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Novosadova","sequence":"additional","affiliation":[{"name":"Momentum Research Inc, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Department of Medicine, Indiana University School of Medicine, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pagnesi","sequence":"additional","affiliation":[{"name":"Cardiology, ASST Spedali Civili and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Institute of Heart Diseases, Wroclaw Medical University, Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadiza","family":"Saidu","sequence":"additional","affiliation":[{"name":"Murtala Muhammed Specialist Hospital \/ Bayero University Kano, Kano, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Sliwa","sequence":"additional","affiliation":[{"name":"Cape Heart Institute, Department of Medicine and Cardiology, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takagi","sequence":"additional","affiliation":[{"name":"Momentum Research Inc, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozine M.","family":"Ter Maaten","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Tomasoni","sequence":"additional","affiliation":[{"name":"Cardiology, ASST Spedali Civili and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan","family":"Voors","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mebazaa","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM UMR-S 942(MASCOT), Paris, France"},{"name":"Department of Anesthesiology and Critical Care and Burn Unit, Saint-Louis and Lariboisi\u00e8re Hospitals, FHU PROMICE, DMU Parabol, APHP.Nord, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"hoi230063r1","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jacc.2008.04.028","article-title":"Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).","volume":"52","author":"Abraham","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"hoi230063r2","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jacc.2013.11.053","article-title":"The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.","volume":"63","author":"Ambrosy","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"hoi230063r3","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/ejhf.v24.9","article-title":"Long-term survival after acute heart failure hospitalization: from observation to collaborative interventions.","volume":"24","author":"Antohi","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"10367","key":"hoi230063r4","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability, and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised trial.","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"hoi230063r5","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/ejhf.v23.7","article-title":"Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum.","volume":"23","author":"Bistola","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"hoi230063r6","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1002\/ehf2.v8.3","article-title":"Adherence and optimization of angiotensin converting enzyme inhibitor\/angiotensin II receptors blockers and beta-blockers in patients hospitalized for acute heart failure.","volume":"8","author":"Carubelli","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"24","key":"hoi230063r7","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study.","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"issue":"8","key":"hoi230063r8","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.amjcard.2018.01.006","article-title":"Effect of optimizing guideline-directed medical therapy before discharge on mortality and heart failure readmission in patients hospitalized with heart failure with reduced ejection fraction.","volume":"121","author":"Yamaguchi","year":"2018","journal-title":"Am J Cardiol"},{"issue":"2","key":"hoi230063r9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/ejhf.2018.20.issue-2","article-title":"Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study.","volume":"20","author":"Gayat","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"hoi230063r10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life.","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy"},{"issue":"4","key":"hoi230063r11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1198\/000313005X70371","article-title":"Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimator.","volume":"59","author":"Snapinn","year":"2005","journal-title":"Am Stat"},{"issue":"1","key":"hoi230063r12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/sim.v3:1","article-title":"A nonparametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus nonresponder bias.","volume":"3","author":"Simon","year":"1984","journal-title":"Stat Med"},{"issue":"11","key":"hoi230063r13","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of survival by tumor response.","volume":"1","author":"Anderson","year":"1983","journal-title":"J Clin Oncol"},{"issue":"2","key":"hoi230063r14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jacc.2012.11.005","article-title":"Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.","volume":"61","author":"Metra","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"hoi230063r15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jchf.2015.01.007","article-title":"Worsening heart failure following admission for acute heart failure: a pooled analysis of the PROTECT and RELAX-AHF studies.","volume":"3","author":"Davison","year":"2015","journal-title":"JACC Heart Fail"},{"issue":"6","key":"hoi230063r16","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.cardfail.2021.01.006","article-title":"Interleukin-6 and outcomes in acute heart failure: an ASCEND-HF substudy.","volume":"27","author":"Perez","year":"2021","journal-title":"J Card Fail"},{"issue":"40","key":"hoi230063r17","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1093\/eurheartj\/eht393","article-title":"Readmission and death after an acute heart failure event: predictors and outcomes in sub-Saharan Africa: results from the THESUS-HF registry.","volume":"34","author":"Sliwa","year":"2013","journal-title":"Eur Heart J"},{"issue":"11","key":"hoi230063r19","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/ejhf.v21.11","article-title":"Acute heart failure congestion and perfusion status\u2014impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA heart failure long-term registry.","volume":"21","author":"Chioncel","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"hoi230063r20","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.v25.12","article-title":"Early changes in renal function changes during rapid up-titration of guideline-directed medical therapy following an admission for acute heart failure.","author":"Ter Maaten","journal-title":"Eur J Heart Fail"},{"issue":"13","key":"hoi230063r21","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","article-title":"Acetazolamide in acute decompensated heart failure with volume overload.","volume":"387","author":"Mullens","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"hoi230063r22","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/eurheartj\/ehac689","article-title":"Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial.","volume":"44","author":"Trulls","year":"2023","journal-title":"Eur Heart J"},{"key":"hoi230063r18","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2022"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2813200\/jamacardiology_cotter_2023_oi_230063_1706752510.55879.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T11:02:12Z","timestamp":1707908532000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2813200"}},"subtitle":["A Secondary Analysis of the STRONG-HF Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2023.4553","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}